Drug intelligence / Profile preview

KP-413

Development stage: Discontinued
Lead developer: Kaken Pharmaceutical
Modality: Small Molecules
Administration: Topical

Overview

KP-413 is a small molecule topical agent that was developed by Kaken Pharmaceutical for the treatment of atopic dermatitis. It functions as an immunomodulator, though its precise mechanism of action remains unknown. The drug underwent phase 1/2 clinical trials to assess its safety, tolerability, and efficacy in adults with atopic dermatitis. Despite initial development efforts, further advancement was discontinued and the drug has not been approved or marketed in any country[1][2][3][8].

Beyond the preview

Go deeper on KP-413.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KP-413.

Explore the full profile